Safe use of a once ‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail

This case report demonstrates that using a non-approved long-acting GLP-1-RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control. AbstractThis case report demonstrates that using a non-approved long-acting GLP-1-RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research